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The effect of a latent infection, and an acute infection of
Toxoplasma gondii on a metastasizing tumor, was studied in C57BL/6J
mice. The metastasizing tumor employed was B16 melanoma (F- subline).
B16 melanoma cells were intravenously injected into mice immediately,
and seven days after an intraperitoneal injection of 10 trophozoites of
Toxoplasma gondii. A latent infection of Toxoplasma gondii was esta
blished in C57BL/6J mice using sulfadiazine. Two weeks after the termi
nation of sulfadiazine, B16 melanoma cells were injected intravenously;
two concentrations of B16 melanoma cells were employed throughout the
study. All mice were sacrificed twenty-one days following B16 melanoma
injections. The lung of each mouse was removed and examined for pulmo
nary metastases. An acute infection of Toxoplasma gondii was shown to
have an enhancing effect on B16 melanoma cells; where as a latent infec-
iii
tion was shown to inhibit proliferation of the tumor. The results of
this study indicate that whether Toxoplasma gondii has an inhibitory or
an enhancing effect on B16 melanoma cells depends on the activity status
of the immune system.
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Toxoplasma gondii, an intracellular protozoan, is one of the most
prevalent parasites known to man. In vitro and in vivo studies have
revealed that T\_ gondii may persist in the tissues of its host indefi
nitely and, because of this persistent activity, it is capable of pro
viding a constant immunogenetic stimulus which results in a continuous
population of activated macrophages. These activated macrophages have
been observed to be cystostatic or cytocidal to tumor target cells.
These effects have been demonstrated in vivo and in vitro (Krahenbuhl
and Lambert, 1975; Remington et al., 1975).
T. gondii activated macrophages have been shown to inhibit the
growth of transplantable as well as autochthonous tumors in vivo (Rem
ington et al., 1971). The objective of this study is to determine if
Toxoplasma gondii will inhibit the growth of a metastasizing tumor.
B16 melanoma, a mouse tumor, and its syngeneic host, C57BL/6J mice,
were employed as the model to study the effects of T_^ gondii on tumor
metastasis. This system was chosen because B16 melanoma cells, when
injected intravenously into C57BL/6J mice, result in lung metastases.
The metastases can be visualized as black nodules lodged in the lung
(Fidler, 1973b). These nodules are very distinct and can be counted
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very easily. Therefore, this system provides a means of quantitating
the effects of T^ gondii on melanoma metastases in the mouse.
There exist many strains of T^ gondii in nature. However, to test
its effect on metastases, the avirulent C56 strain was employed. The
C56 strain of T_^ gondii, when injected into C57BL/6J mice, allows for
two important observations to be made in studying the effects of T_^
gondii on melanoma metastases. C57BL/6J mice have a low susceptibility
to T_^ gondii infections and when injected with the avirulent C56 strain
a considerable period of time expires before the mice succumb, thus
providing time to observe the effect of an acute infection of T^ gondii
on melanoma metastases. On the other hand, a latent infection of the
C56 strain of T^ gondii can be established in C57BL/6J mice using the
drug sulfadiazine. Once a latent infection is established, T_^ gondii
will persist indefinitely without causing death to the mice.
The present study is designed to observe the effects of Toxoplasma
gondii on melanoma metastases in vivo. Because enumeration of the
nodules in the mouse lung provides an excellent means of quantitating
the effects of 1\_ gondii infections on melanoma metastases and because
the C56 strain of T^ gondii has low virulence for C57BL/6J mice, B16
melanoma cells and C57BL/6J mice were employed as the model for this
study. The effect of an acute infection of T_^ gondii and the effect of




Toxoplasma gondii was isolated by Nicolle and Manceaux from a North
African rodent, Ctenodactylus gondii, in 1908. It is classified as an
obligate coccidian protozoan possessing characteristics that allow it to
infect a wide range of warm-blooded animals. It is known that all cells
except nonnucleated erythrocytes can be infected by Toxoplasma gondii
(Feldman, 1974). Toxoplasma gondii divides by endodyogeny (Sulzer et
al., 1958). Its only definitive host is the Felidae. That is, it is in
the Felidae that the entire life cycle of Toxoplasma gondii, including
the development of oocysts, takes place.
Toxoplasmosis, the disease caused by T_^ gondii, was first reported
in 1923 by Dr. Janku (Neto, 1975). The disease is ubiquitous; however,
the incidence varies from population to population. For example, a low
incidence of toxoplasmosis is found among Navaho Indians. On the other
hand, ninety percent of the population of Tahiti has been exposed to T.
gondii by the age of twenty.
Toxoplasma gondii is transmitted by the ingestion of raw meats
(Desmonts and Couvreur, 1973). However, fecal contamination, the inges
tion of raw eggs, and the handling of cats, all have been associated
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with the transmission of T\_ gondii (Feldman, 1974). The parasite also
can be transmitted through the placenta from mother to fetus in utero
(Remington, 1964).
Although a variety of warm-blooded animals can be infected with T^
gondii, the degree of susceptibility of animals to T_^ gondii varies.
Experimental mice, rabbits, hamsters and guinea pigs have been found to
be more susceptible to T^ gondii than rats, dogs, or chickens. Among
experimental mice, Araujo et al.(1977) observed that C57BL/6J mice are
less susceptible to T^ gondii infections than many other strains of
mice. This variation of susceptibility among mouse strains has been
attributed to genetic factors (Williams et al., 1978). However, the
variation also has been attributed to the strain of T^ gondii. Many
strains of T^ gondii have been reported since its discovery in 1908.
The RH strain, isolated from a patient with encephalitis, is the most
virulent strain known. There exist many avirulent strains of T_^ gondii
in nature. The C56 strain, which was isolated from the oviduct and the
ovary of a chicken, is extensively used in experimental studies (Jacobs
et al, 1961).
Toxoplasma gondii may persist in the tissues of animals, as well as
man, indefinitely (Remington and Cavanaugh, 1965). This persistence is
known as a latent T^ gondii infection. Latent infections in experi
mental animals may be established by chemotherapeutic suppression of the
parasite. Such suppression is achieved by the addition of sulfadiazine
to the drinking water of T^ gondii infected mice (Remington et al,
1969). The spleen has been observed to enlarge significantly during a
latent infection of T_^ gondii. This enlargement may be due to a signi-
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ficant increase of blastogenesis which takes places in the spleen during
T^ gondii infections (Hudlt. 1967). Huff et al. (1976) observed that
splenectomized mice were highly susceptible to T^ gondii infections.
This observation suggests that the spleen plays an active role in regu
lating T^ gondii infections.
Immunity to Toxoplasma gondii
It is well established that the immune system plays a major role in
Toxoplasma gondii infections. Toxoplasma gondii may persist in its host
for a lifetime (Remington and Cavanaugh, 1965) and confer resistance
against a lethal challenge dosage (Jacobs, 1953). Immunization against
T_^ gondii has been demonstrated by Remington et al. (1972b) using a
killed vaccine as well as live protozoans as the inoculum. Frenkel
(1969) observed that upon surviving an acute T_^ gondii infection, the
parasite encysts and may remain in the host indefinitely as a latent
infection. Frenkel (1967) established that immunity to T^ gondii can be
transferred by immune T lymphocytes, immune spleen cells, and immune
lymph nodes.
Role of Macrophages in Toxoplasma gondii Infections
Macrophages obtained from mice chronically infected with T^ gondii
or other microorganisms such as Bacillus Calmette-Guerin (BCG), Besno-
itia jellisoni and Listeria monocytogenes are described as activated
macrophages. These macrophages have altered metabolism and morphology
(Suter and Ramseier, 1964). Their most salient features are their
ability to adhere to glass surfaces, to enhance bacteriostasis for a
variety of microbes, and to destroy or inhibit the growth of tumor
cells. In a review on the mechanism of activated macrophages, David
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(1975) suggested that the mediators of activated macrophages are soluble
factors produced by lymphocytes, which are known collectively as lympho-
kines. In a review of mediators of cellular immunity (Cohen et al.,
1977), it was shown that there exist lymphokines specific for the migra
tion inhibition properties of neutrophils and macrophages, lymphokines
that affect surface properties of macrophages and lymphocytes, and
lymphokines that activate various inflammatory cells. There may exist
many other specific lymphokines. Unfortunately, it is not known if one
or all lymphokines are involved in the mechanism of macrophage activa
tion.
It is well known that activated macrophages play an essential role
in T_^ gondii immunity. Using labeled uridine, Remington et al. (1972a)
observed that activated macrophages enhance the killing of or inhibit
the growth of T_^ gondii in vivo. Both lymphocyte proliferation and
macrophage involvement were observed by Reikvam (1976) when mice were
infected with T^ gondii.
Jones et al. (1977) deciphered the mechanism by which macrophages
inhibit the multipilication of, or kill, T_^ gondii. Immune lymphocytes
and macrophages in contact with T_^ gondii antigen, induce immune lympho
cytes to release a lymphokine (Toxoplasma Inhibitory Factor) which
interacts with a glycoprotein on the surface of the macrophage.
Role of Toxoplasma gondii in Microbial and Tumor Immunity
Remington and Ruskin (1968) observed that mice infected with T^
gondii resisted challenge to Listeria monocytogenes and Salmonella
typhimurium. T^ gondii has been observed to confer resistance against a
variety of phylogenetic unrelated organisms, such as Mengo virus and
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Cryptococcus neoformans (Remington and Merigan, 1969; Gentry and Reming
ton, 1971). Remington et al.(1971) demonstrated that an infection with
T^ gondii or Besnoitia jellisoni will confer resistance to Sarcoma 180
and Friend leukemia in Swiss Webster mice, to leukemia 1210 in DBA/2
mice, to spontaneous mammary carcinoma in C3H/HE retired breeders, and
to spontaneous leukemia in AKR mice.
Hibbs et al. (1972) revealed that peritoneal macrophages from
chronically infected J_^ gondii mice nonspecifically destroyed L-cells,
sarcoma KHT syngeneic tumors and allogeneic mammary adenocarcimona EMT-6
cells in vitro. Phagocytosis of the tumor cells was not observed;
however, aggregation of activated macrophages and degenerative changes
in the target cells were observed by phase microscopy. Macrophages from
chronically infected mice have been observed to show a marked cytostatic
effect on tumor target cells, whereas lymphocytes from these infected
mice showed no cytostatic effect when incubated with target cells (Rem
ington et al. 1974). Further studies by Remington et al. (1977) indi
cated nonspecific inhibition of tumor growth in the central nervous
system on mice chronically infected with T_^ gondii. Activated macro
phages were implicated as effector cells in the resistance to intra-
cerebral ependymoblastoma. This resistance has been attributed to the
persistent activity of T_^ gondii within its host, resulting in the
continuing activation of macrophages (Hibbs et al., 1975). Krahenbuhl
and Lambert (1975) hypothesized that cell-to-cell contact between func
tional effectors and tumor target cells is necessary for cytostasis.
The foundation for this hypothesis was the observation that cytostasis
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was significantly decreased when culture conditions discouraged direct
contact between T^ gondii induced activated macrophages and tumor (L-
929) target cells, whereas enhancement of cytostasis was observed when
culture conditions favored direct contact of activated macrophages and
tumor target cells. Contrary to this hypothesis, Calderon et al. (1974)
suggest that cytostasis is the result of a soluble factor secreted by
macrophages. This suggestion came about when culture fluids from macro
phages were found to stimulate DNA synthesis of thymocytes and spleen
cells.
Melanoma
Melanoma in humans was first recognized as neoplasia by a French
physician, Laennec. In humans, these tumors arise from the mucuous
membranes, choroid of the eye, and pigmented components of the skin
(Lewis, 1974). However, it also represents a highly malignant tumor
that often metastasizes throughout the body (Ewing, 1922). The problem
of this malignancy rests on how a collection of benign abnormal melano-
cytes, known as a neavus or a mole, becomes a widespread malignant
tumor. Over fifty percent of patients with melanoma report that the
disease arose from a preexisting naevi or mole. It should be noted,
however, that all naevi or moles are not precursor of melanomas (Nord-
lund and Lerner, 1977).
Three distinct types of melanomas have been described clinically
and pathologically: lentigo maligna, superficial spreading and nodular
melanomas. However, one form of melanoma does not evolve into another.
Humans with fair complexions most frequently develop melanomas. A low
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incidence of melanomas occurs in Blacks. However, in Blacks, the tumors
usually arise from areas which are lightly-pigmented, such as the palm,
soles and mucous membranes (Nordlund and Lerner, 1977).
B16 melanoma, a mouse tumor, may be used as an experimental model
for studying melanoma metastases in humans. B16 melanoma originated
spontaneously in a C57BL/6J mouse at Jackson Laboratories in Bar Harbor,
Maine in 1954. Various tumor lines have been derived from the original
B16 melanoma cell line. The derived sublines have properties with low
or high metastatic abilties. This was accomplished by dissecting tumor
nodules from the lung and maintaining them in tissue culture for a
designated period of time, and then injecting the cells back into their
syngeneic host, C57BL/6J mice. The procedure was repeated several
times, resulting in cells of various metastastic properties. For exam
ple, the F1 subline is a low metastasic tumor line which originated from
the first in vitro passage (Fidler, 1975b).
Invasion and Metastasis of Tumor Cells
According to Fidler (1975c) the development of cancer in vivo in
volves five steps: (1) invasion of cells from the primary tumor into
surrounding tissue and penetration of blood and/or lymph vessels; (2)
release of tumor cell emboli into the circulation; (3) arrest of the
emboli in small vascular channels of distant organs; (4) tumor cell
invasion of the wall of the arresting vessel, infiltration into adjacent
tissue, and multiplication, and (5) growth of vascularized stroma into
the new tumor. Secondary tumor growth results from the final develop
ment of arrested tumor emboli. Willis (1949) observed that although
tumor cell emboli are usually found in the first organ encountered, the
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lung and the liver are the most frequent sites of arrested tumor cell
emboli. He attributed the frequency of arrested tumors in the lung and
liver to the fact that venous blood drains into these organs.
Gasic et al. (1973) studied the role of platelets in malignant
disease. It was observed that many tumors aggregate platelets in vitro
and/or produce thrombocytopenia in vivo. They also observed that metas-
tases produced by a variety of murine tumors are reduced by thrombocyto
penia. Studies with test cells showed B16 melanoma cell line 30 aggre
gated platelets in vitro and produced lung metastases only, whereas B16
melanoma cell line 72 did not aggregate platelets and were distributed
to other organs. Metastases were most often found in the liver and
least often in the lung. This finding indicated that the retention of
arrested cells by the lung is increased by aggregation of platelets.
This suggest that agents which inhibit platelet function may be sig
nificant in reducing metastasis.
Fidler (1970), using labeled B16 melanoma cells, observed that most
intravenously injected tumor cells die and a small fraction survive. It
was noted also that most of the surviving cells become trapped in the
first major capillary bed encountered. It has been found that the
recirculation of tumor cells depends on tumor cell properties. Zeidman
(1961) attributed the rate at which tumor cells pass through capillaries
to their ability to deform.
It is known that resulting numbers of lung metastases are propor
tional to the number of viable tumor cells inoculated (Zeidman, 1957;
Fidler, 1973c). Fidler (1974a) demonstrated that an intravenous injec
tion of clumped tumor cells survived better and produced lung metastases
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more consistently than single cells. The investigator also noted that
lymphocytes combine with tumor cells to form clumps and that they are
more readily trapped in a distant organ such as the lung (Fidler,
1973a).
The Role of Lymphocyte-Macrophage Interaction in the
Growth of B16 Melanoma Cells
Fidler (1973a) reported that sensitized lymphocytes at a ratio of
1,000:1 significantly enhanced the growth of B16 melanoma cells, whereas
lymphocyte ratios higher that 1,000:1 had an inhibiting effect on these
tumor cells. To determine if macrophages were involved in the high
lymphocyte ratio and responsible for the inhibition, Fidler (1975a)
studied the effects of syngeneic lymphocytes and macrophages on B16
melanoma in vitro. Using cells from immune mice, he showed that 10,000
lymphocytes per tumor cell were required to inhibit tumor growth, where
as a ratio of 100:1 macrophages from immune mice inhibited the growth of
the tumor. This suggested that an inhibitory effect may be observed if
lymphocytes are contaminated with only 1% macrophages.
Bartholomaeus et al.(1974) immunized C57BL/6J mice using an anti-
genic preparation made from B16 melanoma cells. These mice showed the
production of cytotoxic, complement fixing, and reaginic antibodies to
these antigens. It was observed that lymphocytes of the spleen and
lymph nodes were stimulated to synthesize DNA when cultured with B16
antigen. Lymphocytes of the spleen inhibited the growth of B16 melanoma
in vitro during tumor growth, whereas lymphocytes of the regional nodes
stimulated tumor growth. The quantity of macrophages was observed to
increase in the tumor during tumor growth. Fidler (1975a) examined
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macrophages from normal C57BL/6J mice, mice having a subcutaneous B16
melanoma, and mice immunized against B16 melanoma. It was found that
only macrophages from immunized mice were cytotoxic to tumor cells.
However, it was observed that macrophages from normal and tumor-bearing
mice became cytotoxic to tumor cells after the incubation with super
natant from cultures containing lymphocytes from sensitized rats, sensi
tized allogeneic mice or immunized syngeneic mice. Fidler (1974b)
demonstrated that when macrophages treated specifically in vitro with
normal, nonspecifically sensitized or specifically sensitized xenogeneic
rat lymphocytes were injected intravenously, but not intraperitoneally,
the number of established pulmonary nodules was significantly reduced.
The Role of BCG in B16 Melanoma Malignancy
Bacillus Calmette-Guerin (BCG) was isolated by Calmette and Guerin
at the Pasteur Institute of Lille from the attenuation of a virulent
strain of Mycobacterium bovis. BCG, like T^ gondii, has been observed
to confer resistance to a host of phylogenetically unrelated organisms
and to many tumor types (Charparas et al., 1973; Mardiney et al., 1973).
Although BCG has been found to inhibit the growth of various tumors, it
also has been found to have an enhancing effect on tumors, depending on
the sex, age of the experimental animal, injection route of BCG or mode
of specific immunization. Hibbs (1975) demonstrated that peritoneal
macrophages from mice infected with BCG were highly cytotoxic to tumori-
genic cells when BCG was injected intraperitoneally. However, if BCG
was injected into a lateral vein or right gastrocnemius muscle the
macrophages failed to become cytotoxic. It was noted also that the
expression of nonspecific resistance to tumor growth in the peritoneal
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cavity correlates with the presence of high levels of BCG antigens and
with activated macrophages possessing nonspecific cytotoxic effects for
tumor cells.
Hanna et al., (1972), using transplanted syngeneic hepatocarcinoma
in guinea pigs, demonstrated that BCG-induced tumor regression was
associated with a massive infiltration of macrophages into the tumor
site and regional nodes. Progressive growth of the tumor was associated
with a lymphoproliferative response in the regional lymph nodes without
the infiltration of macrophages when BCG was absent. Hibbs (1974)
showed that macrophages from mice chronically infected with BCG are
cytotoxic against tumor cells in vitro and that lysosomal enzymes of
macrophage orgin are the mediators of this cytotoxicity.
BCG-infected mice, according to the dose of inoculum, have been
found to resist B16 melanoma cells. A low dose (0.005 mg) of BCG accel
erated the growth of the tumor, whereas a high dose (0.5mg) inhibited
the growth of B16 melanoma cells. It was also found that immune lymph
node cells, when incubated with tumor cells at a low ratio (25:1 -
200:1), enhanced the growth of the tumor. When incubated at a high
ratio (400:1-1,000:1) with tumor cells, lymph node cells inhibited the
growth of the tumor (Chee et al., 1974). Proctor et al. (1975) observed
that when BCG is given ten days before tumor inoculation resistance to
tumor growth will occur, regardless of the route of inoculation. BCG is
now being used extensively in cancer immunotherapy. It has been used
effectively in the treatment of malignant melanoma and other metastas-





The C56 strain of Toxoplasma gondii was obtained from Dr. Jack
Remington of Stanford University, Palo Alto, California, and was em
ployed throughout the experiment.
Mice
C57BL/6J eight week old mice were purchased from Cumberland View
Farms, Clinton, Tennessee. The C56 strain of Toxoplasma gondii was
carried in Swiss Webster (SW) retired breeders which were obtained from
the Center for Disease Control, Atlanta, Georgia.
Tumor Cells
B16 melanoma cells (F. subline) were obtained from Dr. I. J. Fidler
of Frederick Cancer Research Center, Frederick, Maryland.
Preparation of Sulfadiazine
500 mg of sulfadiazine and 46 mg of NaHCCL were dissolved in 1000
ml of distilled water.
Preparation and Inoculation of Toxoplasma gondii
It is well known that SW mice are highly susceptible to T^ gondii.
Because of this phenomenon, SW mice were inoculated with 10 tropho-
zoites of the C56 strain. Seven days after the inoculation, tropho-
zoites were obtained from the peritoneal cavity of these mice. The
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peritoneal exudate was centrifuged, resuspended in Hank's Balanced Salt
Solution (HBSS), and counted in a hemacytometer. Trophozoites were then
inoculated intraperitoneally into C57BL/6J mice.
Preparation and Inoculation of B16 Melanoma Cells
B16 melanomas were carried in their syngeneic host, C57BL/6J mice.
These mice received 10 tumor cells intraperitoneally and were sacri
ficed three weeks later. Tumor cells obtained from the peritoneal
cavity of these mice were collected as friable masses. The masses were
passed through a 50 mesh stainless steel screen, collected in RPMI 1640,
centrifuged and resuspended in fresh RPMI 1640.
The Effects of an Acute Toxoplasma gondii
Infection on B16 Melanoma Cells
B16 melanoma cells were injected intravenously into C57BL/6J mice
seven days following T\_ gondii inoculation. T^ gondii and B16 melanoma
cells were also injected into C57BL/6J mice simultaneously. Two concen
trations of tumor cells were employed independently. A control group of
mice injected with tumor cells but no T_^ gondii was employed for each
concentration. Also, a control group of mice infected with T^ gondii,
but without tumor cells, was employed at each designated T^ gondii
injection time. To confirm an acute infection in these C57BL/6J mice, a
lethal challenge dose (10 trophozoites) was administered to a group of
non-tumor bearing mice seven days post T_^ gondii infection. A lethal
challenge dose was also given to a group of mice having no T^ gondii.
The date of inoculation of the lethal challenge dose corresponded to the
date of the injection of B16 melanoma cells. All mice were sacrificed
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three weeks after the injection of B16 melanoma cells. The lung of each
mouse was examined for tumor nodules. All nodules found per lung were
counted and all lungs were placed in 10% buffered formalin for section
ing.
The Effects of a Latent Infection
of Toxoplasma gondii on B16 Melanoma Cells
A latent infection was established by initiating sulfadiazine
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therapy 72 hours after the inoculation of 10 trophozoites intraperito-
neally, and maintaining the mice on the drug for three weeks (Remington
et al., 1969b). Two weeks after the termination of sulfadiazine, vary
ing numbers of B16 melanoma cells were inoculated intravenuously into
these mice. Three control groups were employed in this experiment:
1. Two concentrations of tumor cells were inde
pendently inoculated into mice having no T_^
gondii;
2. A group of mice inoculated with T_^ gondii
received neither sulfadiazine treatment nor
B16 melanoma cells;
3. A group of mice possessing no T^ gondii was
started on sulfadiazine and terminated simul
taneous with T_^ gondii infected mice. These
mice received B16 melanoma cells two weeks
after the termination of sulfadiazine.
A group of T_^ gondii infected sulfadiazine treated mice was given a
lethal challenge dose of the C56 strain. All mice were sacrificed three
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weeks following tumor cell injections. The lung of each mouse was
examined for tumor nodules; nodules found per lung were quantitated.
Spleens were removed from each mouse and weighed, and all lungs were
placed in 10% buffered formalin for sectioning.
Passive Hemagglutination Test
Sera from tumor bearing T^ gondii-infected mice were tested to de
termine if antibodies to T_^ gondii were present. This was achieved by
inactivating all sera for 30 minutes at 56° C. Following the inactiva-
tion of the sera 0.05 ml of serum from each mouse was added to 0.05 ml of
phosphate buffered rabbit serum in sample wells. Wells containing mouse
serum and buffered rabbit serum were placed on a mechanical vibrator.
While on the vibrator, 0.025 ml of sensitized sheep red blood cells were
added to the wells. The wells were then allowed to stand at room temper
ature for \\ hours. A positive agglutination reaction was indicated with
serum from each tumor bearing T. gondii-infected mouse.
CHAPTER IV
EXPERMENTAL RESULTS
Histological Demonstration of B16 Melanoma
Lung Metastases
Figure 1 shows arrested B16 melanoma cells in the lung. These black
nodules are very distinct and can be counted very easily. Lung section
ing (Fig. 2) reveals that tumor nodules are embedded within the tissues
of the lung and are not merely attached to the surface. Figure 2 indi
cates also that the tumor is encapsulated. It is demonstrated in Figure
that as two tumor nodules proliferate, they will merge. Although each
nodule is individually encapsulated, the arrow indicates the point where
the nodules are coming together and are sharing one capsule. Perhaps
two or more nodules that have merged are represented by the larger
nodules on the surface of the lung in figure 1.
Susceptibility of Swiss Webster and
C57BL/6J Mice to Toxoplasma gondii
Swiss Webster (SW) retired breeders were found to be highly sus
ceptible to the C56 strain of T_^ gondii, in comparison with C57BL/6J
mice. Table 1 shows that C57B1/6J mice, when inoculated with 10 tro-
phozoites, survived for a minimum of 37 days, whereas the same inoculum
into SW mice caused death in 13 days. It was determined from this
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experiment that 10 trophozoites would be the standard inoculum to be
used throughout the study. This decision rested upon the length of the
18
Fig. 1 The lung from a C57BL/6J mouse injected
intravenously with 5 X 10 B16 melanoma





Fig. 3 Sectioning of a lung from a C57BL/67 mouse injected with
Bl6 melanoma cells, the arrow shows the merging of two
nodules.
Fig. 2 Histological section of a lung from a
C57BL/6J mouse injected intravenously with
5 X 10 B16 melanoma cells. The arrow indicates
the capsule surrounding the nodule.
































-•■Each group consisted of five mice.
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time to death in C57BL/6J mice without the use of any drugs. Because of
the high susceptibility of SW mice it was necessary that they be inocu
lated with 10 trophozoites every five to six days for the purpose of
carrying the strain. The trophozoites were obtained from the peritoneal
cavity of previously infected mice.
Challenge Dose
When a lethal challenge dose was adminstered to non-immune T.
gondii infected C57BL/6J mice, death occurred within 8-12 twelve days.
This indicated that these mice possessed an acute T_^ gondii infection.
Chronic T^ gondii - infected mice were observed to resist a lethal chal
lenge dosage. However, normal mice receiving the challenge dose at the
same time as chronically infected mice, died within approximately 10
days. This resistance of a second T_^ gondii inoculation confirmed a
latent T^ gondii infection in mice which received B16 melanoma cells
(Remington et al., 1974). Mice chronically infected with T_^ gondii
showed no symptoms of toxoplasmosis at any time after the inoculation of
the challenge dose. Transfer of brains from chronically infected mice
produced trophozoites in normal SW mice. It should be noted that a
lethal challenge dose was the genesis of death in acute T. gondii in
fected mice and normal mice at approximately the same time.
Metastases of B16 Melanoma Cells in C57BL/6J Mice
Table 2 shows that the number of nodules in the lung was propor
tional to the concentration of tumor cells injected. Although there is
great variation in the number of nodules within a given group, a com
parison of the means from these groups indicated the increase in the
Table 2. Does response of B16 melanoma (F^) in C57BL/6J mice
Number B16 Melanoma Cell No. Resulting Mean
Injected Intravenously Pulmonary Nodules Number
5 X 104 10, 30, 36, 17, 44, 24 22.8
5 X 105 40, 18, 70, 90, 21, 14 42.1
5 X 106 44, 86, 99, 19, 78, 28 59
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number of nodules in each group. This data is similar to the findings
of Zeidman (1957) and Fidler (1974).
Metastases of B16 Melanoma (F.) in Mice
Acutely Infected with Toxoplasma gondii
It is shown in Table 3 that when tumor cells were injected into
mice having an acute infection of T^ gondii, a increase of pulmonary
nodules resulted. This was shown when tumor cells were inoculated
simultaneously with or seven days post T^ gondii infection
Metastases of B16 Melanoma Cells (F-) in Mice
Latently Infected with Toxoplasma gondii
Latently infected T_^ gondii mice are shown to have reduced the
incidence of lung metastases. Table 4 and table 5 indicate the results
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of the inoculation of 5 X 10 tumor cells and 5 X 10 tumor cells re
spectively. Both tables indicate that sulfadiazine had no effect on the
growth of tumor cells. That is, no significant difference was observed
between the number of resulting pulmonary metastases of mice treated
with sulfadiazine only and mice injected only with tumor cells. How
ever, a decrease of pulmonary nodules was observed in mice with a latent
T. gondii infection. This decrease of pulmonary nodules in mice with a
latent T_^ gondii infection is shown in Table 4 and Table 5.
Spleen Weights of Latently Toxoplasma gondii Infected Mice
It is shown in Table 6that B16 melanoma cells caused no significant
increase or decrease in the weight of the spleen when compared to the
spleen weights of normal mice. T_^ gondii was shown to cause a signifi
cant weight increase of the spleen. Mice infected with T^ gondii and
B16 melanoma cells also possessed spleens of increased weights. No
Table 3. Metastases of B16 melanoma (Fi) in acutely Toxoplasma gondii infected mice
Time After Infection1 No. Resulting Mean
Pulmonary Nodules Number
7, 8, 9, 13, 16 10.6
0 days 2, 4, 121, 6, 18, 112 43.8
7 days 1, 11, 27, 3, 45, 254 56.8
mice were infected 5 X 10^ B16 melanoma cells intravenously at the indicated time
after the inoculation of 10^ trophozoites of Toxoplasma gondii.
''Control mice received no Toxoplasma gondii.
3Mice were sacrificed 21 days after melanoma cells injection.
Table 4. Metastases of B16 melanoma (5 X 10^) in latently Toxoplasma gondil
infected mice
Experimental Groups No. Resulting Mean
Pulmonary Nodules^ Number
_T. gondii B16 melanoma
injected mice 0, 0, 0, 6 1.5
Sulfadiazine treated;
B16 melanoma injected mice 49, 54, 47, 58 52.8
B16 melanoma injected mice 54, 58, 43, 38, 44 47.4
mice were injected with 5 X 105 B16 melanoma cells intravenously,
mice were sacrificed 21 days after the injection of tumor cells.
Table 5. Metastases of B16 melanoma (5 X 10^) in latently injected Toxoplasma gondii mice
Experimental Groups No. Resulting Mean
Pulmonary Nodules^ Number
Toxoplasma; B16 melanoma




B16 melanoma injected mice 74, 81, 86, 79, 90 82
B16 melanoma injected mice 83, 94, 34, 90, 104 82.6
-'■All mice injected with 5 X 10-* B16 melanoma cells intravenously.
9
All mice were sacrificed 21 days after the injection of tumor cells.
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significant difference was observed in the spleen weights of these mice
when compared with mice infected with T_^ gondii only. This finding
suggests that T^ gondii infection itself is responsible for the weight
increase.
30
Table 6. Effect of latent Toxoplasma gondii infection and B16
melanoma metastases on the spleen weight of C57BL/6J mice
Experimental Groups B16 Melanoma Gram Weight
Cell Inoculum of Spleen
B16 melanoma controls









bl6 melanoma injected mice






























C57BL/6J mice, the syngeneic host of B16 melanoma cells, have the
abilty to endure a T_^ gondii infection for a considerable period of time
before succumbing. This susceptibility of C57BL/6J mice to T_^ gondii
made it possible to observe the reaction of the immune response to B16
melanoma in mice with an acute infection or a latent infection of T.
gondii.
This study provided evidence that T^ gondii may have an enhancing
effect or an inhibitory effect on tumor metastases, depending on the
type of infection. That is, an acute T_^ gondii infection in C57BL/6J
mice was observed to cause an increase of tumor metastases, whereas a
latent T_^ gondii infection conferred resistance to B16 melanoma metas
tases.
This study suggests that tumoricidal effector cells, induced by a
latent T_^ gondii infection, are effective in the destruction of metas-
tasizing tumors, as they are in autochtonous and transplantable tumors
(Remington et al. 1971). However, this study suggests also that macro-
phages were not responding to B16 melanoma cells as tumoricidal effector
cells during an acute T_^ gondii infection. This can be attributed to,
as suggested by Keller (1975), that different activities of the macro-
phage result in different soluble factors, having and enhancing or an
31
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inhibitory effect on tumor target cells. Consequently, it may also be
as observed by Reikvam (1976) that macrophages do not take on the cha
racteristics of activation until approximately 14 days after a T^ gondii
infection, and at this time a significant increase of macropahge prolif
eration takes place. Perhaps when B16 melanoma cells were injected
simultaneous with T^ gondii into C57BL/6J mice, as well as when B16
melanoma cells were injected seven days after the injection of T^ gon
dii, macrophages were not activated. It may be that macrophages were
only partially activated, if such a state exist. These nonactivated
macrophages, instead of inhibiting may enhance tumor growth. However,
as they become activated or as the immune system becomes stronger
against the J_^ gondii infection, tumor cell growth is inhibited. This
type of immune response would explain the increase of lung metastases
when B16 melanoma cells were injected simultaneously with T. gondii, and
seven days after the injection of T. gondii. If the immune system was
forced to respond to T^ gondii and to a metastasizing tumor simultane
ously, its effectiveness may have been altered, thus causing an increase
of lung metastases.
When the immune system was allowed to establish a strong defense
against T_^ gondii prior to the injection of B16 melanoma cells, the
growth of B16 melanoma cells was inhibited. The inhibition is attri
buted to the fact that the immune system defense mechanisms were very
active at the time of the injection of tumor cells. This study supports
the theory of Prehn and Lappe (1971) that the immune response to neo-
plasia may have a dual role. They theorized that if the immune system
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is weak or activity is at a minimum tumor growth may be stimulated.
However, if the immune system is initially active an inhibition of tumor
growth may occur. Fidler (1974a), who supports the theory of Prehn and
Lappe (1971), demonstrated that when a small number of immune lympho
cytes are injected into C57BL/6J mice an increase of pulmonary metas-
tases occurs. However, an injection of large numbers of immune lympho
cytes causes a reduction of pulmonary nodules. It was also observed by
Keller (1973) that when macrophages are few in number in vivo, the
growth of tumor cells is enhanced. These observations suggest that
during an acute T_^ gondii infection the immune system is weak and it may
stimulate only a minimum amount of macrophages, which results in an
increase of lung metastases. Apart from the functional activities of
macrophages it has been suggested by Keller (1975) that tumor cell
enhancement can be attributed to the macrophage-tumor cell ratio, the
susceptibility of the target cell, and the anatomical relationship
between macrophages and tumor cells.
BCG has been found to confer resistance to B16 melanoma cells in
C57BL/6J mice depending on the dosage injected (Chee and Boduratha,
1974). Although a dose response of T^ gondii to B16 melanoma cells was
not employed in this study, the results indicated T. gondii like BCG, is
a microbe capable of inhibiting tumor metastases. Independently, BCG
and T. gondii are capable of activating macrophages to become tumori-
cidal effector cell. It has been observed that activated macrophages
induced by BCG or T^ gondii, destroy target cells by mechanisms other
than phagocytosis (Hibbs et al., 1972; Hibbs, 1974). Hibbs (1974) noted
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that lysosomal enzymes from the macrophage are secreted directly into
the cytoplasm of the tumor cell, thus causing tumor destruction. Since
macrophages can become activated by many foreign agents, including BCG
and T_^ gondii, one may speculate that the same type of destructive
mechanism that takes place when BCG-activated macrophages and tumor
cells interact, occurs when T^ gondii-activated macrophages and tumor
cells interact. That is, lysosomal enzymes from these activated macro
phages may also be the mediator of 816 melanoma destruction.
BCG immunotherapy has been found effective in inhibiting and re
gressing melanoma in many animals, including humans (Kein et al., 1973;
Pinsky et al., 1973). It also has been observed by Davignon et al.
(1970) that children routinely vaccinated with BCG have a low incidence
of leukemia when compared to children not routinely vaccinated. Based
on these observations and on the fact that T^ gondii may persist in its
host indefinitely, it is hypothesized that in populations where the
parasite is prevalent, there exist a low incidence of cancer. This
hypothesis should be developed epidemiologically, and if it is shown to
be a fact immediate research should be undertaken to employ a J_^ gondii
vaccine which may be used as a vaccine for cancer. This study suggests
that a T. gondii vaccine may significantly decrease the incidence of
cancer; however, it also suggests that extreme precautions be taken, for
if an acute reaction is induced the incidence of cancer may increase.
CHAPTER VI
SUMMARY
1. An acute infection of Toxoplasma gondii in C57B1/6J mice has an
enhancing effect on B16 melanoma tumor growth.
2. A latent infection of Toxoplasma gondii in C57BL/6J mice has a
inhibitory effect on B16 melanoma tumor growth.
3. Depending on the effect of the parasite on the immune system, Toxo
plasma gondii may have an inhibitory or an enhancing effect on B16
melanoma metastases in C57BL/6J mice.
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